Egetis Therapeutics AB EGTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- SEK 4.39
- Day Range
- SEK 4.33–4.33
- 52-Week Range
- SEK 3.83–9.30
- Bid/Ask
- SEK 4.33 / SEK 4.45
- Market Cap
- SEK 1.28 Bil
- Volume/Avg
- 2,777 / 442,908
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 17.68
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Egetis Therapeutics AB is an integrated pharmaceutical drug development company, focusing on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 33
- Website
- https://www.egetis.com
Comparables
Valuation
|
Metric
|
EGTX
|
CALTX
|
FLERIE
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 0.20 |
Price/Book Value | 3.20 | 104.39 | 0.76 |
Price/Sales | 17.68 | 6.92 | 2,263.89 |
Price/Cash Flow | — | — | — |
Price/Earnings
EGTX
CALTX
FLERIE
Financial Strength
|
Metric
|
EGTX
|
CALTX
|
FLERIE
|
|---|---|---|---|
Quick Ratio | 1.55 | 2.59 | 31.25 |
Current Ratio | 1.56 | 2.69 | 31.25 |
Interest Coverage | −22.42 | −5.22 | −175.65 |
Quick Ratio
EGTX
CALTX
FLERIE
Profitability
|
Metric
|
EGTX
|
CALTX
|
FLERIE
|
|---|---|---|---|
Return on Assets (Normalized) | −49.14% | −28.79% | −10.31% |
Return on Equity (Normalized) | −65.52% | −174.85% | −10.73% |
Return on Invested Capital (Normalized) | −56.41% | −36.60% | −12.52% |
Return on Assets
EGTX
CALTX
FLERIE
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Ptzvdmckc | Npy | $554.5 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Zzchhykg | Cvnvkbn | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Lbxgxtdg | Hvjrswl | $114.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Knkqlfvk | Nwmyzp | $35.2 Bil | |||
| argenx SE ADR
ARGX
| Zbcdkzxp | Pfrql | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Xfhxmjhm | Nxtg | $28.0 Bil | |||
| Moderna Inc
MRNA
| Bcwwwhbgb | Mvv | $24.6 Bil | |||
| United Therapeutics Corp
UTHR
| Myqrpbn | Vnmt | $15.9 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Nkqwwttwy | Bxghbzv | $13.4 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Zhnfddcvj | Kskpz | $12.6 Bil |
United States